loading page

Durable  and Dramatic Response to Checkpoint Inhibition Combined with COX-2 Inhibitor Celecoxib in a Patient with p16+  Metastatic Sinonasal Undifferentiated Carcinoma: A Case  Study            
  • +2
  • Jonathan Trinh,
  • Cassaundra Acosta,
  • Arti Easwar,
  • Robert Galamaga,
  • Alan Tan
Jonathan Trinh
University of Nebraska Medical Center

Corresponding Author:[email protected]

Author Profile
Cassaundra Acosta
Arti Easwar
Author Profile
Robert Galamaga
Author Profile
Alan Tan
Rush University Medical Center
Author Profile


Background: Sinonasal undifferentiated carcinoma (SNUC) is an exceedingly rare head and neck malignancy. No consensus exists on treatment for metastatic disease.
Case: A 56-year-old female was diagnosed with SNUC after endorsing sinus congestion, diplopia, and right orbital pain. Initially treated with surgery and radiation, she later developed significant metastatic disease. She demonstrated progression of her hepatic metastases under pembrolizumab therapy. However, the addition of ipilimumab and a COX-2 inhibitor resulted in significant improvement in her lesions as well as an ongoing durable response. Her regimen was complicated by immune-related adverse events successfully treated with steroids.
Conclusion: Dual checkpoint inhibition deserves consideration when treating metastatic SNUC, especially after single agent therapy has failed. The positive effect of this treatment may be augmented by IDO1 inhibition.
17 Nov 2022Submitted to Cancer Reports
09 Dec 2022Submission Checks Completed
09 Dec 2022Assigned to Editor
09 Dec 2022Review(s) Completed, Editorial Evaluation Pending
24 May 2023Reviewer(s) Assigned
26 Jun 2023Editorial Decision: Revise Major
05 Aug 20231st Revision Received
31 Aug 2023Assigned to Editor
31 Aug 2023Submission Checks Completed
31 Aug 2023Review(s) Completed, Editorial Evaluation Pending
31 Aug 2023Reviewer(s) Assigned
17 Sep 2023Editorial Decision: Revise Minor
02 Oct 20232nd Revision Received
03 Oct 2023Assigned to Editor
03 Oct 2023Submission Checks Completed
03 Oct 2023Review(s) Completed, Editorial Evaluation Pending
08 Oct 2023Editorial Decision: Accept